Session » Genetics, Genomics and Proteomics - Poster I

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 79

A NOVEL Missense Mvk mutation in a Family with Familial Mediterranean Fever-like Disease

9:00AM-11:00AM: Abstract Number: 71

A Rare Coding Allele in IFIH1 is Protective for Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 60

A Single Nucleotide Polymorphism of IL6-Receptor Is Associated with Response to Tocilizumab in Rheumatoid Arthritis: Results from Toci and ROC Studies

9:00AM-11:00AM: Abstract Number: 56

A Systems Biology Approach to Investigating Beneficial Effects of Endurance Exercise in Myositis Patients

9:00AM-11:00AM: Abstract Number: 74

Arthritis-Associated DNA Hypermethylation Provokes Increased Antibody Expression in Mouse Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 76

Chromatin Interactions Reveal Novel Gene Targets for Drug Repositioning in Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 58

Detecting Novel Candidate Risk Genes in Rheumatoid Arthritis with Gene-Based Association Testing

9:00AM-11:00AM: Abstract Number: 73

Dysregulation of Hypomethylated Age-Related CpG Sites Characterize T-Cells and Monocytes from Treatment Naive Rheumatoid Arthritis Subjects

9:00AM-11:00AM: Abstract Number: 64

Enrichment of Immune Pathways in Genes Under Geographically Restricted Adaptation in the Gullah African American Population of South Carolina

9:00AM-11:00AM: Abstract Number: 68

Epigenetic and Expression Analysis of Ankylosing Spondylitis Association Loci Point to Key Cell Types Driving Disease

9:00AM-11:00AM: Abstract Number: 75

Genetic Analysis of Urate Transporters ABCG2, SLC17A3, SLC22A11 and SLC17A1 in Primary Hyperuricemia and Gout

9:00AM-11:00AM: Abstract Number: 65

Genetic Heterogeneity in the Risk of Lupus Nephritis According to Ancestry

9:00AM-11:00AM: Abstract Number: 57

Genetic Polymorphism of IL-1RN Encoding the IL-1 Receptor Antagonist Predicts Radiographic Severity of Symptomatic Knee OA

9:00AM-11:00AM: Abstract Number: 55

Identification of Endogenous Autoantigens Bound to Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis: A Key Role for Citrulline Residues in Histone 4

9:00AM-11:00AM: Abstract Number: 63

Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 70

Identifying Distal Interactions Between RUNX1 and JIA Associated Single Nucleotide Polymorphisms By Chromosome Conformation Capture

9:00AM-11:00AM: Abstract Number: 69

IL-32 Promoter SNP rs4786370 Predisposed to Modified Lipoprotein Profiles in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 62

Increased Frequency of Anti-Drug Antibodies in Patients Carrying Compatible IgG1 Allotypes and Treated with Anti-TNF Antibodies

9:00AM-11:00AM: Abstract Number: 77

Integrated Analysis of Microrna and mRNA Expression Profiles Related to Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome Patients

9:00AM-11:00AM: Abstract Number: 61

Killer Immunoglobulin-like Receptors Are Associated with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 72

Longitudinal Expression of CXCL10 in Psoriasis Patients That Develop Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 59

Novel Agents for Blocking the Interaction of Immune Complexes with the Activatory FcγRIIIa Receptor

9:00AM-11:00AM: Abstract Number: 67

Polymorphisms of ERAP1, IL23R and TRAILR1 Are Associated with MRI-Sacroiliitis in Early Axial Spondyloarthritis: Data from the French DESIR Cohort

9:00AM-11:00AM: Abstract Number: 66

Very Rare X Chromosome Abnormalities in SLE and SjöGren’s May Localize X Gene Dose Effect

9:00AM-11:00AM: Abstract Number: 78

Whole Blood Gene Modules Show Differences Between Active Lupus Nephritis and Quiescent Disease As Well As Absence of Plasmablast Signature in This Adult Population

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].